Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase II Study of Simvastatin in Women at High Risk for a New Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00334542
• Other study ID #: J0485
• Secondary ID: P50CA088843P30CA
• Status: Completed
• Phase: Phase 2
• Start date: March 2006
• Est. completion date: November 2011

Study information

• Verified date: March 2019
• Source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin may keep cancer from coming back in women who are at high risk for a new breast cancer after undergoing surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cancer.

PURPOSE: This phase II trial is studying how well simvastatin works in preventing a new breast cancer in women at high risk for a new breast cancer after undergoing surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cancer.

Description:

OBJECTIVES:

Primary

• Describe changes from baseline in a panel of biomarkers (high-sensitivity C-reactive protein [hsCRP], lipid profile, circulating estrogens, and contralateral breast density) in women at high risk of developing new breast cancer who have undergone surgical resection for history of ductal carcinoma in situ or stage I-III invasive breast cancer treated with simvastatin.

Secondary

• Correlate changes in the panel of biomarkers with wild-type versus polymorphic 3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase in women treated with simvastatin.

Tertiary

• Evaluate methylation status across a panel of genes that are known to be frequently and specifically hypermethylated in ductal carcinoma in situ (DCIS) and invasive breast cancer (estrogen receptor [ER]-α and ER-β, cyclin D2, RAR-β, Twist, RASSF1A, and HIN-1) and correlate change in cumulative methylation with change in hsCRP, lipid profile, contralateral breast density, estrogen concentrations, and pharmacogenetics.

• Measure changes in the phosphoinositide 3'-kinase (PI3K)/protein kinase B (Akt) signaling pathway (Akt and p-Akt) before and after treatment with simvastatin.

OUTLINE: This is a multicenter study. Patients are stratified according to menopausal status (pre- vs post-menopausal).

Patients receive oral simvastatin once daily for 24-28 weeks in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection at baseline and at the end of study treatment for pharmacogenetic and biomarker correlative studies. Patients undergo mammography and measurement of breast density of the contralateral breast at baseline and at the end of study treatment.

Quality of life is assessed at baseline and at the end of study treatment.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: November 2011
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• History of histologically confirmed breast cancer, meeting 1 of the following staging criteria:

• Ductal carcinoma in situ

• Stage I-III invasive breast cancer

• At least 3 months since completion of all intended local and systemic therapy, including mastectomy or lumpectomy with or without radiotherapy, adjuvant chemotherapy, and/or endocrine therapy

• May have declined recommended treatment provided all treatment intended/agreed upon by the patient and treating physician was completed = 3 months ago

• At least 1 healthy intact breast

• No prior radiotherapy or mastectomy

• Prior biopsies allowed

• Any hormone-receptor status

PATIENT CHARACTERISTICS:

• Female

• Pre- or post-menopausal

• ECOG performance status 0-2

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective nonhormonal contraception

• No active liver disease

• AST and ALT = 3 times upper limit of normal

• Creatinine clearance = 30 mL/min

• No prior hypersensitivity to any 3-hydroxyl-3-methylglutaryl-Coenzyme A (HMG-CoA) reductase inhibitor or any of its components

• No other concurrent infectious, inflammatory, or autoimmune diseases (at the discretion of principal investigator)

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No daily alcohol use > 3 standard drinks per day

• Standard drink defined as 10 grams of alcohol, which is equivalent to 285 mL of beer, 530 mL of light beer, 100 mL of wine, or 30 mL of liquor

• No selective estrogen receptor modulator or aromatase inhibitor within the past 3 months

• No hormone replacement therapy (HRT) within the past 3 months

• No prior estrogen and/or progesterone HRT = 5 years in duration

• Vaginal estrogen preparations allowed

• No concurrent HRT

• No other cholesterol-lowering drug, including a statin, within the past 3 months

• No concurrent itraconazole, ketoconazole, nefazodone, cyclosporine, HIV protease inhibitors, clarithromycin, erythromycin, mibefradil, carbamazepine, bosentan, chaparral, amiodarone, or verapamil

• No concurrent daily grapefruit juice consumption > 8 ounces per day

• No other concurrent agents or therapies intended to treat or prevent in situ or invasive breast cancer

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• simvastatin
24-28 weeks of simvastatin

Locations

Country	Name	City	State
United States	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland
United States	Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, Sukumar S. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res. 2004 Jul 1;64(13):4442-52. — View Citation

Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, Jeter SC, Armstrong DK, Davidson NE, Emens LA, Fetting JH, Powers PP, Wolff AC, Green H, Thibert JN, Rae JM, Folkerd E, Dowsett M, Blumenthal RS, Garber JE, Stearns V. A short-term bioma — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in a Panel of Biomarkers (High-sensitivity C-reactive Protein [hsCRP], Lipid Profile, and Circulating Estrogens) From Baseline		Baseline and week 24
Primary	Change in a Panel of Biomarkers (Contralateral Breast Density) From Baseline		Baseline and week 24
Secondary	Prevalence of Breast Gene (Estrogen Receptor [ER]-a and ER-ß, Cyclin D2, RAR-ß, Twist, RASSF1A, and HIN-1) Hypermethylation	Median change in gene promotor methylation (%M) in the contralateral breast of women with breast cancer after six months of therapy	Change from Baseline to week 24
Secondary	Prevalence of Akt and p-Akt Activation by Contralateral Core Breast Biopsies		Baseline and week 24